Fig. 4

MOG-Fc mitigates EAE in C57BL/6 mice. a–c EAE incidence (a), mean clinical score (b), mean maximal scores (c) after immunization of C57BL/6 mice with MOG 35–55 in CFA (MOG-Fc n = 14, SD-Fc n = 14). Data from 2 experiments are pooled. ****P < 0.0001 (log-rank Mantel–Cox test). d–h The numbers of total (d), IFNγ⁺ (e), IL-17⁺ (f), IFNγ⁺ IL-17⁺ (g) and Foxp3⁺ (h) CD4⁺ T cells in the spinal cords of healthy (asymptomatic) and sick mice treated with MOG-Fc or SD-Fc (MOG-Fc healthy n = 4, MOG-Fc sick n = 2, SD-Fc sick n = 7). Each circle represents an individual mouse. d *P = 0.0359, SD-Fc sick vs MOG-Fc healthy; f *P = 0.0164, SD-Fc sick vs MOG-Fc healthy; h **P = 0.0082, SD-Fc sick vs MOG-Fc sick, *P = 0.0401, MOG-Fc sick vs MOG-Fc healthy. All data are represented as mean ± s.e.m. An unpaired T-test with Welch’s correction was used for group comparisons